A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy AdultsAndrás Nagy, Zhaoyang Li, Alexander Bauer et al.|Journal of Clinical Immunology|2023Cited by 3
60 Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study designRichard LWasserman, Zhaoyang Li, András Nagy et al.|Clinical Immunology|2024Cited by 0